AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $63.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$63.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 1 cutMore adding
Key stats
Fundamentals Sep 30- Open
- $98.43
- 52-wk high
- $124.00
- High
- $99.79
- 52-wk low
- $79.52
- Low
- $97.60
- Prev close
- $99.08
- Mkt cap
- $24.76B
- Volume
- 737.0K
- Fwd P/E
- 7.0x
- Beta
- 1.29
- P/S
- 9.3x
- P/B
- 1.2x
- Profit margin
- -63.6%
- Op margin
- -807.0%
- ROE
- -9.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BNTX filings
Are insiders buying or selling BioNTech SE (BNTX) stock?
Net selling: insiders sold $63.7M and bought $0 of BNTX stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $63.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Sahin, Ugur (Chief Executive Officer), who sold $63.7M. The latest filing was on Sep 30, 2026.
Which members of Congress have traded BNTX recently?
None. No member of Congress disclosed a BNTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this BNTX smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- BA
Balyasny
$34.8M
added
- P7
Point72
$30.4M
bought
Sells/Trims (1)
- CI
Citadel
$50.6M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in BNTX right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 17.4% below what analysts expected.
Earnings per share
-$2.58 expected
Reports Nov 2, 2026, in 32 days
Estimates as of Sep 30, 2026
EPS expected
$0.39 to $1.35
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -63.6%
- Forward P/E
- 7.04
- Market cap
- $24.8B
Valuation
- P/S9.34
- P/B1.22
Quality
- Operating margin-807.0%
- ROE-9.3%
- ROA-5.4%
Growth
- Beta1.29
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
BioNTech stock trades at EUR 86.05 after a revenue miss
Leans bearishSep 30A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares.
Leans bearishSep 28BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts
BearishSep 28Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
Leans bullishSep 28BioNTech to close 3 German plants
BearishSep 28Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
NeutralSep 28How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
BullishSep 27BioNTech SE (22UA.F) Stock Price, News, Quote & History
NeutralSep 25
Macro
10 macro signals shaping BNTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results